Monoclonal antibodies offer key opportunities in precision immunotherapy for cancer and chronic diseases. Focus areas include targeted novel therapies, stereo-specific antibodies for enhanced efficacy ...

Vascular Endothelial Growth Factor Inhibitor market grows 4.0% CAGR as biosimilars and personalized medicine expand ...

Eli Lilly and Company (NYSE:LLY) is included among the 16 Best Dividend Stocks with Rising Payouts. According to a Reuters ...

The Australian company will retain rights for an end-stage kidney disease indication currently being tested in a Phase 3 trial while Lilly explores other uses.

Coherus BioSciences shows underwhelming LOQTORZI sales and reliance on upcoming pipeline catalysts. Read why CHRS stock is ...

Leronlimab-mediated CCR5 blockade modulates T-Cell exhaustion pathways and PD-L1 Biology relevant to ICI responseDurable Clinical Observations ...

Zenyaku Kogyo obtains Japanese approval for anti-CD20 monoclonal antibody, Rituxan to treat autoimmune haemolytic anaemia: Tokyo Friday, February 20, 2026, 13:00 Hrs [IST] Zenyaku ...

Australia's CSL said on Wednesday it has granted Eli Lilly certain rights to develop and commercialize clazakizumab, an ...

Over 95% of the world's adult population is infected with Epstein-Barr virus (EBV), but most people never realize it. The infection often causes few symptoms and then stays in the body for life.

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to ...

Adults with primary membranous nephropathy achieved higher complete remission rates with obinutuzumab than tacrolimus in the pivotal phase 3 MAJESTY trial.

The FDA's top drug regulator indicated in her first address to staff that she will scrutinize antidepressants and shots used to protect babies from RSV ...